Walgreens Boots Alliance, Inc. (NASDAQ:WBA) To Release Earnings


(NASDAQ:WBA) that has shown a discernible change in trend levels over the path of recent market activity.

Walgreens Boots Alliance reported a 7.9 per cent sales hike for the three months to 30 November 2017, an increase of 7.2 per cent on a constant currency basis.

A number of research firms have recently issued reports on WBA. The total amount of shares outstanding is 1.14B, giving the company a market capitalization of about 38.11B. Zacks Investment Management now owns 3,979 shares of the pharmacy operator's stock worth $321,000 after buying an additional 11 shares during the period. Hudock Capital Group LLC lifted its holdings in Walgreens Boots Alliance by 0.5% during the 2nd quarter.

At the moment 25 analysts are watching Walgreens Boots Alliance, Inc. Institutional investors and hedge funds own 61.18% of the company's stock.

Walgreens Boots Alliance, Inc (Walgreens Boots Alliance) is a holding company. (NASDAQ:WBA) opened at 85.99 on Wednesday. Walgreens Boots Alliance Inc has a 52-week low of $63.82 and a 52-week high of $88.00.

More news: National Football League to consider knee injury during concussion protocol investigation
More news: NFL Investigating Raiders' Possible Rooney Rule Violation After Jon Gruden Hire
More news: Spurs will keep Kane and Alli this summer

As for guidance, Walgreens Boots Alliance did increase the low end of its fiscal full-year earnings per share outlook by $0.05 to $5.45 to $5.70. For example, an impairment associated with its equity method investment in Guangzhou Pharmaceuticals Corporation was the primary reason why GAAP diluted net earnings per share declined 16.5% to $0.81 from one year ago. The firm had revenue of $28.50 billion for the quarter. For the quarter ending Feb-18, 18 analysts have a mean sales target of 32,214.10 million whilst for the year ending Aug-18, 21 analysts have a mean target of 129,885.00 million. During the same period in the previous year, the business posted $1.07 EPS. equities research analysts forecast that Walgreens Boots Alliance Inc will post 5.54 EPS for the current year.

The firm also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. This represents a $1.60 dividend on an annualized basis and a yield of 2.12%. The ex-dividend date of this dividend is Monday, February 13th. Whether or not Walgreens Boots Alliance, Inc. fits your portfolio, at the very least you will have a greater understanding of the Services and Drug Stores. BidaskClub raised shares of Walgreens Boots Alliance from a "strong sell" rating to a "sell" rating in a research note on Friday, November 10th. The average analysts gave this company a mean recommendation of 2.20. One analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have given a buy rating and one has given a strong buy rating to the company's stock.

Walgreens Boots Alliance's price-to-earnings ratio stands at 19.88x, which is low, relative to the industry average.

In other news, COO Ornella Barra purchased 124,000 shares of the business's stock in a transaction that occurred on Tuesday, February 7th. The shares were bought at an average cost of $67.00 per share, with a total value of $1,340,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. The most recent short interest data show 2.79% of the company's stock are short sold. Shares price moved down from its 50 days moving average with 6.13% and remote positively from 200 days moving average with 17.05%. Shares repurchase plans are typically a sign that the company's board of directors believes its shares are undervalued. The disclosure for this sale can be found here. But, since Walgreens Boots Alliance is a high-growth stock, we must also account for its earnings growth by using calculation called the PEG ratio.

Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for glaucoma and other diseases of the eye in the United States.